<DOC>
	<DOCNO>NCT01508247</DOCNO>
	<brief_summary>Since discovery 1969 , enterovirus 71 ( EV71 ) recognise frequent cause epidemic hand-foot-mouth disease ( HFMD ) associate severe neurological sequela small proportion case . There significant increase EV71 epidemic activity throughout Asia-Pacific region since 1997 . Recent HFMD epidemic region heen associate severe brainstem encephalitis associate pulmonary oedema high case-fatality rate . The data phase 1 2 trial suggest inactivated EV71 vaccine clinically acceptable safety good immunogenicity healthy Chinese child infant . According immunogenicity safety result , 320U adjuvant immunize schedule two dos ( per 28 day ) apply phase 3 clinical trial .</brief_summary>
	<brief_title>A Clinical Trial Assess Efficacy Safety Inactivated Vaccine ( Vero Cell ) Against EV71 Chinese Children Aged 6-35 Months</brief_title>
	<detailed_description />
	<mesh_term>Mouth Diseases</mesh_term>
	<mesh_term>Foot-and-Mouth Disease</mesh_term>
	<mesh_term>Hand , Foot Mouth Disease</mesh_term>
	<mesh_term>Herpangina</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Only subject fulfil follow criterion eligible study : Healthy child age 6 35 month old General good health establish medical history physical examination The subject ' guardian able understand sign inform consent Had never receive vaccine EV71 The subject ' guardian allow comply requirement protocol Available visit schedule study Subjects temperature &lt; =37.0°C axillary setting Subjects eligible study follow criterion meet : Subject medical history HFMD Subject medical history following : allergic history , allergic ingredient vaccine Family history seizure progressive neurological disease Family history congenital hereditary immunodeficiency Severe malnutrition hypogenesis Major congenital defect serious chronic illness , include perinatal brain damage Autoimmune disease Bleeding disorder diagnose doctor significant bruising bleed difficulty IM injection blood draw Asplenia , functional asplenia , splenic excision History asthma , angioneurotic edema , diabetes malignant tumour History thyroidectomy , thyroid disease last 12 month Any acute infection last 7 day Any prior administration immunodepressant corticosteroid last 6 month Any prior administration blood product last 3 month Any prior administration research vaccine medicine last 1 month Any prior administration attenuate live vaccine last 15 day Any prior administration subunit inactivate vaccine last 7 day Under antiTB prevention therapy Subjects temperature &gt; 37.0°C axillary set Any condition opinion investigator , may interfere evaluation study objective Exclusion Criteria second dose : Subjects eligible second dose follow adverse event happen first dose . They continue process study without second dose vaccination accord opinion investigator . Had serious adverse event relate first dose inactivate vaccine ( vero cell ) EV71 within 7 day Hypersensitivity reaction vaccination ( include urticaria/rashes occur within 30 minute inoculation ) Anaphylaxis vaccination Any confirm suspect autoimmune disease immune deficiency disease , include human immunodeficiency virus ( HIV ) infection Any condition opinion investigator , IRB</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>inactivate vaccine ( Vero Cell ) EV71</keyword>
	<keyword>EV71-associated disease</keyword>
</DOC>